No connection

Search Results

AYTU vs KYNB

AYTU
Aytu BioPharma, Inc.
NEUTRAL
Price
$2.70
Market Cap
$27.5M
Sector
Healthcare
AI Confidence
65%
KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AYTU
--
KYNB
--
Forward P/E
AYTU
15.88
KYNB
-0.7
P/B Ratio
AYTU
1.15
KYNB
-0.97
P/S Ratio
AYTU
0.43
KYNB
4.51
EV/EBITDA
AYTU
3.86
KYNB
0.13

Profitability

Gross Margin
AYTU
67.56%
KYNB
-273.8%
Operating Margin
AYTU
-10.83%
KYNB
-1058.65%
Profit Margin
AYTU
-20.52%
KYNB
2848.63%
ROE
AYTU
-50.23%
KYNB
--
ROA
AYTU
0.61%
KYNB
-16.96%

Growth

Revenue Growth
AYTU
-16.2%
KYNB
-59.3%
Earnings Growth
AYTU
--
KYNB
--

Financial Health

Debt/Equity
AYTU
1.23
KYNB
4.37
Current Ratio
AYTU
1.23
KYNB
3.39
Quick Ratio
AYTU
1.0
KYNB
3.19

Dividends

Dividend Yield
AYTU
--
KYNB
--
Payout Ratio
AYTU
0.0%
KYNB
0.0%

AI Verdict

AYTU NEUTRAL

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.

Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)

Compare Another Pair

AYTU vs KYNB: Head-to-Head Comparison

This page compares Aytu BioPharma, Inc. (AYTU) and Kyntra Bio, Inc. (KYNB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile